Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Arrowhead Pharma (ARWR) PT Raised to $29 at Leerink Partners
June 3, 2024 1:33 PM EDTLeerink Partners analyst Mani Foroohar raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $29.00 (from $27.00) while maintaining a Market Perform rating.... More
Arrowhead Pharmaceuticals (ARWR) Reports Successful Results for Plozasiran from the Phase 3 PALISADE Study
June 3, 2024 7:32 AM EDTArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints,... More
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
May 30, 2024 6:13 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $50.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "We hosted CEO for Boston NDR and he came across as very confident on cardiometabolic (particularly on upcoming FCS data, differentiation to... More
